CSF β-amyloid predicts prognosis in patients with multiple sclerosis.
Adult
Amyloid beta-Peptides
/ cerebrospinal fluid
Biomarkers
/ cerebrospinal fluid
Disease Progression
Female
Follow-Up Studies
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis
/ cerebrospinal fluid
Peptide Fragments
/ cerebrospinal fluid
Prognosis
White Matter
/ diagnostic imaging
Biomarkers
MRI
multiple sclerosis
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
pubmed:
8
8
2018
medline:
17
6
2020
entrez:
8
8
2018
Statut:
ppublish
Résumé
The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed. To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta Sixty patients were recruited and followed up for 3-5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aβ levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads. Lower CSF Aβ levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS; Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.
Sections du résumé
BACKGROUND
The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed.
OBJECTIVES
To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta
METHODS
Sixty patients were recruited and followed up for 3-5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aβ levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads.
RESULTS
Lower CSF Aβ levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS;
CONCLUSION
Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.
Identifiants
pubmed: 30084711
doi: 10.1177/1352458518791709
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Peptide Fragments
0
amyloid beta-protein (1-42)
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM